Clinic News

Latest in Cardiology

• TCT 2018 | Video: Highlights - Part 1
  Drs. Peter Block and Deepak Bhatt discuss transcatheter mitral valve leaflet approximation in patients with HF and secondary mitral regurgitation (COAPT); self-expandable vs. balloon expandable valves and general vs. local anesthesia in patients undergoing TAVI (SOLVE-TAVI); pulmonary artery denervation in combined pre- and postcapillary pulmonary HTN (PADN-5).
• Prosthesis-Patient Mismatch After TAVR
  What are the frequency, predictors, and association with outcomes of prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR)?
• PADN-5: PADN vs. Standard Medical Therapy in Patients With CpcPH
  Pulmonary artery denervation (PADN) plus standard medical therapy led to a significant improvement in the 6-minute walk distance (6MWD) and pulmonary vascular resistance (PVR), based on results from the PADN-5 study presented Sept. 23 at TCT 2018 and published in JACC: Interventions.
• A 2x2 Randomized Trial of Self-Expandable vs. Balloon-Expandable Valves and General vs. Local Anesthesia in Patients Undergoing Transcatheter Aortic Valve Implantation
  The goal of the SOLVE-TAVI trial was to compare the safety and efficacy of the Edwards Sapien S3 valve vs. Medtronic’s CoreValve among patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis. Further, in a 2x2 factorial design, the trial also sought to compare conscious sedation vs. general anesthesia in this patient population.
• SOLVE-TAVI: Self-Expanding vs. Balloon-Expandable Valves and Local vs. General Anesthesia in TAVR Patients
  SOLVE-TAVI trial results comparing self-expanding valves with balloon-expandable valves, as well as general vs. local anesthesia, in patients undergoing transcatheter aortic valve replacement (TAVR) build on the currently limited evidence for direct comparisons of latest generation valve designs and anesthesia strategies, said researchers presenting at TCT 2018.
• A Sham-Controlled Randomized Trial of Transcatheter Indirect Mitral Annuloplasty in Heart Failure Patients With Functional Mitral Regurgitation
  The goal of the REDUCE-FMR trial was to assess the safety and efficacy of transcatheter mitral annuloplasty in reducing regurgitant volumes among symptomatic heart failure (HF) patients with dilated left ventricles (LVs) and secondary mitral regurgitation (MR).
• Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation
  The goal of the COAPT trial was to assess the safety and efficacy of transcatheter mitral leaflet approximation using MitraClip among symptomatic heart failure (HF) patients with secondary mitral regurgitation (MR).
• TCT 2018 | Video: COAPT
  Dr. Peter Block provides an overview of the COAPT trial which examined transcatheter mitral valve leaflet approximation in patients with HF and secondary mitral regurgitation.
• COAPT: TMVR in HF Patients With Moderate/Severe MR vs. Medical Therapy Alone
  Transcatheter mitral valve repair (TMVR) resulted in lower rates of hospitalization and all-cause mortality within 24 months for patients with heart failure and moderate/severe secondary mitral regurgitation (MR) who were not responding to maximum doses of guideline-recommended medical therapy alone, said researchers presenting findings from the COAPT trial at TCT 2018.
• RESTORE ISR/RESTORE SVD: Safety, Efficacy and Effectiveness of Restore Device in China
  Results from two studies showing the clinical non-inferiority of the Restore paclitaxel-coated balloon in treating in-stent restenosis (ISR) and small-vessel disease (SVD) indication could help enable the approval of the new device in China.